Management of Myopericarditis
Initial Management
- Hospitalization is mandatory for all patients with myopericarditis for monitoring, differential diagnosis with acute coronary syndrome, and surveillance of complications, as recommended by the European Society of Cardiology 1, 2
- Coronary angiography is indicated based on clinical presentation and risk factors to rule out acute coronary syndrome, according to the European Heart Journal 1, 2
- Cardiac magnetic resonance imaging is recommended to confirm myocardial involvement and exclude ischemic myocardial necrosis, as suggested by the European Heart Journal 1, 2
Pharmacological Treatment
- Empirical anti-inflammatory therapies should be considered at the lowest effective doses to control chest pain, as recommended by the European Society of Cardiology 1, 2, 3
- Aspirin 1500-3000 mg/day, divided every 8 hours, is an option for first-line treatment, as recommended by the European Heart Journal 1, 2
- Ibuprofen 1200-2400 mg/day (600 mg every 8 hours) is preferred due to its superior safety profile, according to the European Heart Journal 1, 2
- Indometacin 75-150 mg/day (25-50 mg every 8 hours) should be avoided in the elderly due to reduced coronary flow, as recommended by the European Society of Cardiology 1, 2
Activity Restriction
- Absolute rest and avoidance of physical activity beyond normal sedentary activities are recommended for a minimum period of 6 months from the onset of the disease, as suggested by the European Heart Journal 1, 2, 3
Prognosis
- Myocardial involvement in pericarditis has a good prognosis, and observational series have demonstrated no evolution to heart failure or mortality in patients with myopericarditis, according to the European Heart Journal 1, 3
Common Pitfalls to Avoid
- Do not use full doses of non-steroidal anti-inflammatory drugs (NSAIDs) as in pure pericarditis - use the lowest effective doses due to concerns from animal models, as recommended by the European Society of Cardiology 1, 2, 3
- Do not allow early return to exercise - the 6-month restriction is mandatory regardless of symptomatic improvement, as suggested by the European Heart Journal 1, 3
- Do not assume that colchicine has the same benefit as in pericarditis - there is insufficient evidence in myopericarditis, according to the European Heart Journal 1, 2, 3
- Do not use corticosteroids as first-line treatment - reserve for specific cases, as recommended by the European Society of Cardiology 1, 2
Management of Myocarditis and Pericarditis
Diagnosis and Treatment
- The European Society of Cardiology recommends that the diagnosis of acute pericarditis requires at least 2 of 4 criteria: pericarditic chest pain, pericardial friction rub, widespread ST-elevation or PR depression on ECG, and new or worsening pericardial effusion 4, 5
- Aspirin (1500-3000 mg/day) or NSAIDs (ibuprofen 1200-2400 mg/day or indomethacin 75-150 mg/day) are the mainstay of therapy for acute pericarditis, distributed every 8 hours 4, 6
- Colchicine should be added as adjunctive therapy to improve response and reduce recurrence rates in acute pericarditis 4, 7
- Corticosteroids are NOT recommended as first-line therapy (Class III, Level B recommendation) for acute pericarditis and should only be used for contraindications, intolerance, or failure of aspirin/NSAIDs 4, 8, 7
Activity Restriction
- Non-athletes with acute pericarditis should restrict exercise until symptom resolution and CRP normalization 8, 7
- Athletes with acute pericarditis should have a minimum 3-month exercise restriction until symptom resolution and normalization of CRP, ECG, and echocardiogram 4, 8, 7
- Patients with myopericarditis should have complete rest and avoidance of physical activity beyond normal sedentary activities for a minimum of 6 months from illness onset 5, 6
Myopericarditis Management
- Myopericarditis is diagnosed when patients meet criteria for acute pericarditis AND have elevated cardiac biomarkers (troponin I/T, CK-MB) WITHOUT new focal or diffuse left ventricular dysfunction on echocardiography or cardiac MRI 4, 5, 6
- Empirical anti-inflammatory therapies at the lowest efficacious doses should be considered for myopericarditis, as animal models suggest NSAIDs may enhance myocardial inflammation and increase mortality in pure myocarditis 5, 6
- Aspirin 1500-3000 mg/day or NSAIDs (ibuprofen 1200-2400 mg/day or indomethacin 75-150 mg/day) are prescribed primarily for chest pain control in myopericarditis, but at reduced dosages compared to pure pericarditis 5, 6
Prognosis
- Myopericarditis has an excellent prognosis with no evolution to heart failure or mortality in observational series, despite troponin elevation 5, 6
- The risk of constrictive pericarditis in patients with pericarditis is <1% 4, 8
Management of Myopericarditis
Initial Risk Stratification and Hospitalization
- The European Society of Cardiology recommends that all patients with myopericarditis must be hospitalized for monitoring, exclusion of acute coronary syndrome, and surveillance for complications, regardless of troponin level, as a Class I recommendation 9, 10
Diagnostic Considerations
- Myopericarditis is defined as meeting criteria for acute pericarditis plus elevated troponin without new left ventricular dysfunction on echocardiography 9
Anti-Inflammatory Treatment Protocol
- The European Society of Cardiology suggests using empirical anti-inflammatory therapy at the lowest effective doses to control chest pain, with ibuprofen 1200-2400 mg/day or aspirin 1500-3000 mg/day as preferred options 9
Mandatory Activity Restriction
- Absolute rest and avoidance of physical activity beyond normal sedentary activities for a minimum of 6 months from disease onset is recommended 9